Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Jul. 17, 2012, 11:09 AM
    SA author Stephen Simpson says J&J (JNJ -0.7%) had a decent Q2, with an encouraging underlying performance in the company's drug and orthopedics ops. Simpson's main concern is the devices and diagnostics arms, the latter seeming to be slipping "further and further behind." Still, J&J "looks like a worthwhile name for conservative investors looking for healthcare exposure."
    | Comment!
  • Jul. 17, 2012, 8:12 AM
    More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR)
    | Comment!
  • Jul. 17, 2012, 7:55 AM
    Johnson & Johnson (JNJ): Q2 EPS of $1.30 beats by $0.01. Revenue of $16.5B (-0.7% Y/Y) misses by $200M. Shares -1.2% premarket. (PR)
    | Comment!
  • Jul. 17, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HIST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 10:59 AM
    Johnson & Johnson (JNJ): Declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.6%. For shareholders of record Aug 28; Payable Sep 11; ex-div date Aug 24. (PR)
    | Comment!
  • Jul. 12, 2012, 6:06 AM
    J&J (JNJ) could face a bill of almost $4.8B to cover revision surgery for its Pinnacle metal-on-metal hip system, estimates attorney Brian Devine, who is handling cases in which the device has failed. That would add to the $3B J&J has shelled out following the recall of its ASR all-metal artificial hips two years ago.
    | Comment!
  • Jul. 9, 2012, 8:40 AM
    The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting treatment Xarelto for use against deep vein thrombosis and pulmonary embolism, and the prevention of venous thromboembolism in people who have already had it. However, Bayer withdraws its request to use Xarelto to lower the risk of blood clots in heart-stent patients.
    | Comment!
  • Jul. 8, 2012, 7:41 AM
    Seven DJIA components have hit all-time highs this year (vs. 8 in 2011), with JNJ and AXP seemingly next in line. Many of the blue chips boast strong balance sheets, consistent cash flows, and yields matching or beating Treasurys - adaptive managements are thrown in for free. What's not to like?
    | 21 Comments
  • Jul. 2, 2012, 12:16 PM
    J&J (JNJ +0.4%) is seeking accelerated FDA approval for bedaquiline, the first new type of drug to treat tuberculosis in over four decades, and the first for specifically fighting the increasingly common strain of the disease that is resistant to multiple drugs. J&J filing is supported by data from a Phase II trial. (PR)
    | Comment!
  • Jun. 28, 2012, 10:53 AM
    Pharmaceutical stocks are down following the Supreme Court healthcare opinion, although not dramatically: AZN -0.4%, GSK -1.6%, SNY -0.8%, PFE -0.8%, ABT -0.8%, MRK -0.7%, LLY -1%, WPI -0.9%, NVS -0.7%, JNJ -0.4%. iShares Dow Jones US Healthcare ETF (IYH) -0.95%, the Health Care SPDR (XLV) is -1.3%.
    | 2 Comments
  • Jun. 25, 2012, 2:58 PM
    The FDA will convene an advisory panel meeting this week to discuss metal-on-metal hip implants made by Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%), which have been the subject of thousands of patient lawsuits. The metal devices have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011, according regulators, and need more consistent testing to help lower high failure rates that lead to risky replacement surgeries. (draft report)
    | Comment!
  • Jun. 22, 2012, 1:55 PM
    Johnson & Johnson (JNJ +0.4%) receives a favorable Barron's write-up. The paper talks up J&J's 3.7% dividend yield, low P/E, diverse product line, and new drug launches, along with its recently-closed acquisition of medical device maker Synthes. (earlier)
    | Comment!
  • Jun. 22, 2012, 5:00 AM
    The FDA has blocked J&J's (JNJ) application to widen the use of its Xarelto blood thinner to prevent heart attacks and strokes in people with acute coronary syndrome, a market estimated at $1B. J&J said it will work with the FDA to address their questions, indicating it hasn't given up hope of eventually getting the authorization.
    | 3 Comments
  • Jun. 20, 2012, 7:20 PM
    Johnson & Johnson (JNJ) says it's close to settling a DoJ probe into the off-label marketing of its antipsychotic medication Risperdal. The settlement is expected to be one of the largest for a drug-marketing case, as JNJ and the government discuss a payment of $1.5B - $2B or higher.
    | 3 Comments
  • Jun. 15, 2012, 6:10 PM
    Shares of orthopedics stocks rose today after privately held Biomet said FQ4 sales rose 3.4%. Industry sales have been weak as people delay hip and knee replacement surgeries in the weak economy. Biomet, which reports earlier than peers, is viewed as an indicator for the rest of the industry. The news boosted ZMH +4.2%, SYK +3.5%, WMGI +1.8%, JNJ +0.9%.
    | 1 Comment
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.